Firebrick Pharma (ASX:FRE) has launched its product, Nasodine Nasal Spray in Singapore.
Customers will be able to order the product through Firebrick’s new website dedicated to support Singapore sales: www.nasodine-sg.com
In Singapore, Nasodine is classified as a topical antiseptic and does not require approval or licensing by Singapore’s Heath Sciences Authority (HSA) before sale. However, any advertisements to Singapore consumers need prior approval by the HSA. Firebrick received approval from the HSA for its consumer advertisements on 12 June 2024.
Nasodine will be the first PVP-I nasal spray available in the region and therefore represents a “first-in-class” product.
Nasodine will be promoted in Singapore as “The nasal spray that kills germs”. The main promotional claims will be that it can help defend against the daily threat of germs in situations such as commuting, socialising, working and travelling.
The company recently announced the availability of Nasodine in the USA as a nasal cleanser, with no therapeutic or germicidal claims. In contrast in Singapore, Nasodine can be actively promoted for its germ-killing properties.
“We believe that Nasodine will be a valuable product in the wake of the COVID pandemic because of increased awareness and concern about nasal germs,” said Firebrick Executive Chairman, Dr Peter Molloy.
Initially, Nasodine will only be sold in Singapore online and Firebrick has engaged a Singapore-based marketing agency to manage the online social media promotional campaign. In the future, the product may also be sold through pharmacies and may attract pharmaceutical marketing partners.